March 14, 2024

Drug Trials Snapshots: COLUMVI

HOW TO USE THIS SNAPSHOTThe information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, […]
March 14, 2024

PQ/CMC Federal Register Notices

FDA has released several FRNs over the past few years covering the PQ/CMC project. As new sections of Module 3 eCTD (Electronic Common Technical Document) are […]
March 14, 2024

Q&A with FDA Podcast

“Q&A with FDA” provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of […]
March 14, 2024

Patient Listening Session Summaries

FDA’s Patient Affairs is responsible for managing the Agency’s Patient Listening Session program. This page contains a list of all the Patient Listening Sessions that have been […]
March 14, 2024

Competitive Generic Therapy Approvals

  RLD Name and NDA Number ANDA Number ANDA Applicant Active Ingredient Name, Dosage Form, Strength  Date of Approval Eligible for CGT Exclusivity CGT Exclusivity Forfeiture […]
March 13, 2024

Govvi WOW! contains hidden ingredients

[3-13-2024] FDA reminds consumers not to purchase or use Govvi WOW!. FDA laboratory analysis confirmed an additional sample of Govvi WOW! contained undeclared DMHA, in addition […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0